In one paragraphArticle in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
24 authors at 8 institutions in 3 countries.
Erik C B JohnsonGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, 30329, GA, USA.ORCID 0000-0002-0604-2944 Raquel PuertaResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, 08028, Spain, Barcelona.ORCID 0000-0002-1191-5893 Eric B DammerGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, 30329, GA, USA.ORCID 0000-0003-2947-7606 Anantharaman ShantaramanGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, 30329, GA, USA.ORCID 0000-0003-1384-941X Amanda CanoResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, 08028, Spain, Barcelona.ORCID 0000-0001-9567-4283 Mercè BoadaResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, 08028, Spain, Barcelona.ORCID 0000-0003-2617-3009 Sergi ValeroResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, 08028, Spain, Barcelona.ORCID 0000-0002-6599-948X Pablo García-GonzálezResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, 08028, Spain, Barcelona.ORCID 0000-0003-0125-5403 Anthony P OrthNovartis Biomedical Research, San Diego, 10675, CA, USA.
Nicholas T SeyfriedGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, 30329, GA, USA.ORCID 0000-0002-4507-624X Allan I LeveyGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, 30329, GA, USA.ORCID 0000-0002-3153-502X Agustin RuizResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, 08028, Spain, Barcelona.ORCID 0000-0003-2633-2495 Lenore J LaunerLaboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, 20892, MD, USA.ORCID 0000-0002-3238-7612 University of Iceland · ISEmory University · USInstituto de Salud Carlos III · ESIcelandic Heart Association · ISNovartis (United States) · USGenomics Institute of the Novartis Research Foundation · USNational Institute on Aging · USUniversitat Internacional de Catalunya · ES
Funding
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI DAVID WEINSHENKER · 2020 to 2026
$29.0MSupplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1MSerum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik studyR01AG065596 · NIA · ICELANDIC HEART ASSOCIATION · PI Valborg Gudmundsdottir · 2021 to 2026
$2.6MBrain Proteomic Network Analysis to Elucidate Mechanisms and Biomarkers for Alzheimer's DiseaseK08AG068604 · NIA · EMORY UNIVERSITY · PI JOHNSON, ERIK C.B. · 2020 to 2024
$762kAGES STUDY-THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENNIUM-26012100N01AG012100 · NIA · ICELANDIC HEART ASSOCIATION · 2002 to 2004
–NIA NIH HHS K08 AG068604NIA NIH HHS N01 AG012100NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG065596NIA NIH HHS U01 AG061357NIDA NIH HHS HHSN271201200022C
6 · The paper itselfAbstract
The current demand for early intervention, prevention, and treatment of late onset Alzheimer's disease (LOAD) warrants deeper understanding of the underlying molecular processes which could contribute to biomarker and drug target discovery. Utilizing high-throughput proteomic measurements in serum from a prospective population-based cohort of older adults (n=5,294), we identified 303 unique proteins associated with incident LOAD (median follow-up 12.8 years). Over 40% of these proteins were associated with LOAD
Indexed as
Alzheimer’s diseaseAPOEBrainCross-sectional studyCSFLongitudinal studyMendelian randomizationNetworkProteomics
Identifiers
PMID37986771
PMCPMC10659486
OpenAlexW4388519437
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390